A citation-based method for searching scientific literature

Jessica A Starr, Nathan A Pinner, Katelin M Lisenby, Alyssa Osmonson. Pharmacotherapy 2021
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
100

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
289
100

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
100

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
50

Heart Failure Awareness 2002--and beyond.
Barry H Greenberg. J Card Fail 2002
8
50

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton. Diabetes Obes Metab 2018
182
50

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, Urszula Masiukiewicz, Richard Pratley, Sam Dagogo-Jack, Robert Frederich, Bernard Charbonnel, James Mancuso, Weichung J Shih,[...]. Circulation 2020
58
50



3
50

SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Diogo Santos-Ferreira, Pedro Gonçalves-Teixeira, Ricardo Fontes-Carvalho. Cardiology 2020
8
50



Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Beta-blockers and glucose control.
G A Mills, J R Horn. Drug Intell Clin Pharm 1985
30
50

Metabolism of the failing heart and the impact of SGLT2 inhibitors.
Alvaro Garcia-Ropero, Carlos G Santos-Gallego, M Urooj Zafar, Juan J Badimon. Expert Opin Drug Metab Toxicol 2019
26
50


Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
Salim Yusuf, Bertram Pitt, Clarence E Davis, William B Hood, Jay N Cohn. N Engl J Med 1991
50

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Michael R MacDonald, Mark C Petrie, Fumi Varyani, Jan Ostergren, Eric L Michelson, James B Young, Scott D Solomon, Christopher B Granger, Karl Swedberg, Salim Yusuf,[...]. Eur Heart J 2008
368
50

Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies.
Zijun Ge, Amy Li, James McNamara, Cris Dos Remedios, Sean Lal. Heart Fail Rev 2019
9
50


Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. N Engl J Med 2014
50

Renin-angiotensin-aldosterone system inhibitors in heart failure.
F Shearer, C C Lang, A D Struthers. Clin Pharmacol Ther 2013
30
50

A cardiologist's view of hypoglycemia.
Shailesh Nandish, Jamison Wyatt, Rene Oliveros, Adrienne Stevens Zion, Michael Lujan, Robert Chilton. Curr Atheroscler Rep 2010
4
50

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur J Heart Fail 2016
50

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
188
50

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S Yusuf, P Sleight, J Pogue, J Bosch, R Davies, G Dagenais. N Engl J Med 2000
50

Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
Farheen K Dojki, George Bakris. Curr Opin Nephrol Hypertens 2017
13
50

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
Marvin A Konstam, James D Neaton, Kenneth Dickstein, Helmut Drexler, Michel Komajda, Felipe A Martinez, Gunter A J Riegger, William Malbecq, Ronald D Smith, Soneil Guptha,[...]. Lancet 2009
376
50

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Filipe Ferrari, Vítor M Martins, Rafael S Scheffel, Anderson D da Silveira, Marcelo Trotte Motta, Emilio H Moriguchi, Raul D Santos, Ricardo Stein. Ann Pharmacother 2021
3
50

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
James P Curtain, Kieran F Docherty, Pardeep S Jhund, Mark C Petrie, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine,[...]. Eur Heart J 2021
7
50

Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
Paul G Shekelle, Michael W Rich, Sally C Morton, Col Sid W Atkinson, Wenli Tu, Margaret Maglione, Shannon Rhodes, Michael Barrett, Gregg C Fonarow, Barry Greenberg,[...]. J Am Coll Cardiol 2003
323
50

Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
Juan Simon Rico-Mesa, Averi White, Ashkan Ahmadian-Tehrani, Allen S Anderson. Curr Cardiol Rep 2020
11
50

Beta-blockers and diabetes: the bad guys come good.
John Malcolm Cruickshank. Cardiovasc Drugs Ther 2002
21
50

Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Muhammad Shahzeb Khan, G Michael Felker, Ileana L Piña, Alexander Camacho, Devavrat Bapat, Nasrien E Ibrahim, Alan S Maisel, Margaret F Prescott, Jonathan H Ward, Scott D Solomon,[...]. JACC Heart Fail 2021
8
50

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
Prakash C Deedwania, Thomas D Giles, Michael Klibaner, Jalal K Ghali, Johan Herlitz, Per Hildebrandt, John Kjekshus, Jindrich Spinar, Jiri Vitovec, Hilary Stanbrook,[...]. Am Heart J 2005
94
50

Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial.
Michael S Kiernan, Deborah Wentworth, Gary Francis, Felipe A Martinez, Kenneth Dickstein, Michel Komajda, Faiez Zannad, James D Neaton, Marvin A Konstam. Eur J Heart Fail 2012
21
50

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction.
Daniele Masarone, Maria Luigia Martucci, Vittoria Errigo, Giuseppe Pacileo. J Cardiovasc Dev Dis 2021
1
100


Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.
Matthias Naegele, Andreas J Flammer, Frank Enseleit, Frank Ruschitzka. Swiss Med Wkly 2016
5
50

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel,[...]. Eur Heart J 2021
139
50

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Gerasimos Filippatos, Stefan D Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P Maggioni, Piotr Ponikowski, Adriaan A Voors, Faiez Zannad,[...]. Eur Heart J 2016
150
50

Contemporary Management of Heart Failure in Patients With Diabetes.
James A Shaw, Mark E Cooper. Diabetes Care 2020
6
50



Beta-blocker use for the stages of heart failure.
Marc Klapholz. Mayo Clin Proc 2009
50
50


SGLT2 inhibition and heart failure-current concepts.
Joaquim Silva Custodio, Andre Rodrigues Duraes, Marconi Abreu, Natalia Albuquerque Rocha, Leonardo Roever. Heart Fail Rev 2018
19
50


Eplerenone in patients with systolic heart failure and mild symptoms.
Faiez Zannad, John J V McMurray, Henry Krum, Dirk J van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Stuart J Pocock, Bertram Pitt. N Engl J Med 2011
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.